Publication: A Synthesis of Clinical Research From Mahidol University 2019-2023
Issued Date
2025
Resource Type
Resource Version
Accepted Manuscript
Language
eng
File Type
application/pdf
ISSN
0125-3611 (Print)
2651-0561 (Online)
2651-0561 (Online)
Journal Title
Ramathibodi Medical Journal
Volume
48
Issue
1
Start Page
e271149
Access Rights
open access
Rights
ผลงานนี้เป็นลิขสิทธิ์ของมหาวิทยาลัยมหิดล ขอสงวนไว้สำหรับเพื่อการศึกษาเท่านั้น ต้องอ้างอิงแหล่งที่มา ห้ามดัดแปลงเนื้อหา และห้ามนำไปใช้เพื่อการค้า
Rights Holder(s)
Research Management and Development Division Office of the President Mahidol University
Bibliographic Citation
Ramathibodi Medical Journal. Vol. 48, No. 1 (Jan - Mar 2025), e271149
Suggested Citation
Chaninart Suriyalungga A Synthesis of Clinical Research From Mahidol University 2019-2023. Ramathibodi Medical Journal. Vol. 48, No. 1 (Jan - Mar 2025), e271149. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/110062
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A Synthesis of Clinical Research From Mahidol University 2019-2023
Author(s)
Abstract
Background: Strategic research funding is a potential avenue for financial support. Consequently, the synthesis of previous clinical research projects was conducted to explore the possibility of receiving funds.
Objective: To synthesize the clinical research projects of Mahidol University.
Methods: Research data synthesis was performed on clinical research projects in the database of the Research Management and Development Division, Mahidol University, covering the fiscal year 2019-2023. This synthesis was based on the strategic research funding of Thailand for the years 2023-2027 and the announcement of funding from the Program Management Unit (PMU) for the fiscal year 2023-2024. The results are reported by type classification, quantity, and percentage.
Results: Clinical trial research conducted by Mahidol University during fiscal years 2019-2023, which met the criteria of the program for strategic research funding and qualified for the PMU’s announcement of research funding in the fiscal year 2023-2024, were as follows: 1) vaccine development and production, F1 (S1P1), 43 projects (81.13%); 2) development and production of advanced therapy medicinal products, F2 (S1P1), 15 projects (23.44%); 3) genomics and precision medicine, N1 (S1P1), 17 projects (94.44%); 4) development and production of medicines and herbal extracts, N2 (S1P1), 430 projects (97.28%); and 5) national epidemics and emerging diseases, N15 (S2P10), 11 projects (40.74%).
Conclusions: Clinical trial research according to the program of strategic research funding and eligible for PMU was arranged in descending order as follows: N2 (S1P1), N1 (S1P1), F1 (S1P1), N15 (S2P10), and F2 (S1P1).